KOD
Kodiak Sciences Inc. Health Care Biological Products, (No Diagnostic Substances) Russell 3000
$99.18Close
$6.1BMarket cap
$16.90 – $100.4052-week range
Nov 12, 2026Next report
Highlights
Strengths
- In a stage-2 uptrend all 8 trend conditions pass
- Leading the market RS 99 · stronger than 99% of stocks over 12 months
- RS line at a 1-year high outperforming the S&P 500 more than at any point this year
- Near its high 1% below its 52-week high
- Volume drying up last 10 days 57% under the 50-day average
- Accumulation up-day volume 2.2× down-day volume over 50 sessions
Cautions
- Extended 8.4 ATR above its 50-day average
- Results soon Nov 12, 2026, in 11 days
Price
Filing Results Screen pick 52-week high and low Adjusted prices
Key figures
Off 12-month high
1%
1wk
up 13.2%
price change
1mo
up 4.6%
price change
12-month return
up 371%
market up 11% ·
its own up 413%
F-score
—
— Not assessed
Altman Z
—
Unknown
P/E
—
price / earnings
PEG
—
P/E / EPS growth
P/B
38.9×
price / book
Earnings yield
down 4.0%
EBIT / enterprise value
Cheaper than
—
of the market · not assessed
Revenue growth
—
year on year
EPS growth
—
latest quarter
Sales growth
—
latest quarter
ROE
down 149%
return on equity
Free cash margin
—
-$136.5M FCF
D/E
—
long-term debt / equity
Net debt / EBITDA
—
Interest cover
—EBIT / interest
Trade setup
ATR%
6.7%
$6.60 a day · 2×ATR $85.97
RS
99 / 99
vs the universe
Trend
8 / 8
trend template
Relative volume
0.3×
vs 50-day average
Up/down volume
2.22
50 sessions
Implied move
—
no option chain · report Nov 12, 2026
Trend template · 8 of 8
Screen verdict
Did not qualify for any screen.
Warning signs
- Shareholders diluted The share count rose 17.1% over the year, from 53m to 62m shares. Each existing share owns a smaller fraction of the company than it did a year ago.
Last reported
Aug 13, 2026
Results reaction
Aug 13, 2026-5% vs market2 sessions after results
Financials
- Cash
- Long-term debt
| FY2020Dec 31, 2020 | FY2021Dec 31, 2021 | FY2022Dec 31, 2022 | FY2023Dec 31, 2023 | FY2024Dec 31, 2024 | FY2025Dec 31, 2025 | |
|---|---|---|---|---|---|---|
| Operating income | -$136.0M | -$267.1M | -$341.4M | -$277.3M | -$186.8M | -$234.4M |
| Net income | -$133.1M | -$267.0M | -$333.8M | -$260.5M | -$176.2M | -$230.0M |
| Earnings per share | -$2.91 | -$5.16 | -$6.39 | -$4.97 | -$3.35 | -$4.32 |
| Free cash flow | -$87.2M | -$199.3M | -$243.5M | -$195.5M | -$117.7M | -$136.5M |
| Cash | $944.4M | $731.5M | $190.4M | $285.5M | $168.1M | $209.9M |
| Shareholders' equity | $860.8M | $663.3M | $436.2M | $265.8M | $150.3M | $157.4M |
| Shares outstanding | 51.11m | 51.83m | 52.33m | 52.51m | 52.73m | 61.76m |
Filings
| Filed | Report | Period to | Lag |
|---|---|---|---|
| Aug 13, 2026 | Quarterly ↗ | Jun 30, 2026 | 44d |
| May 7, 2026 | Quarterly ↗ | Mar 31, 2026 | 37d |
| Mar 31, 2026 | Annual ↗ | Dec 31, 2025 | 90d |
| Nov 13, 2025 | Quarterly ↗ | Sep 30, 2025 | 44d |
| Aug 13, 2025 | Quarterly ↗ | Jun 30, 2025 | 44d |
| May 14, 2025 | Quarterly ↗ | Mar 31, 2025 | 44d |
| Mar 27, 2025 | Annual ↗ | Dec 31, 2024 | 86d |
| Nov 14, 2024 | Quarterly ↗ | Sep 30, 2024 | 45d |
| Aug 14, 2024 | Quarterly ↗ | Jun 30, 2024 | 45d |
| May 15, 2024 | Quarterly ↗ | Mar 31, 2024 | 45d |
| Mar 28, 2024 | Annual ↗ | Dec 31, 2023 | 88d |
| Nov 14, 2023 | Quarterly ↗ | Sep 30, 2023 | 45d |
Current reports
| Filed | Disclosed |
|---|---|
| Sep 28, 2026 | Other events ↗ |
| Aug 13, 2026 | Results ↗ |
| Jun 4, 2026 | Shareholder vote ↗ |
| May 7, 2026 | Results ↗ |
| Mar 31, 2026 | Results ↗ |
| Mar 27, 2026 | Other events ↗ |
| Dec 18, 2025 | Other events ↗ |
| Nov 13, 2025 | Results ↗ |
| Aug 13, 2025 | Results ↗ |
| Jun 3, 2025 | Shareholder vote ↗ |
| May 14, 2025 | Results ↗ |
| Mar 27, 2025 | Results ↗ |